This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 36% and 72.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 3.85% and 4.34%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -18.75% and 64.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -14.29% and -18.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Oncternal Therapeutics (ONCT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -20.00% and -32.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics' (ONCT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Oncternal Therapeutics, Inc. (ONCT).
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Oncternal Therapeutics (ONCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
5 Stocks to Buy on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Oncternal Therapeutics (ONCT) stock based on the movements in the options market lately.
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 50.00% and 169.15%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.